A range of health care-related firms have been honored at an awards ceremony held in London, UK, ranging from drug discovery technologies to patient monitoring.
Among the drug industry winners, Zug, Switzerland-based biotechnology firm, AmVac AG, was awarded the 2006 Enabling Technology of the Year Award in the Biotherapeutic Drugs and Treatment Procedures Market.
AmVac was launched in 2005 and has two advanced biotherapeutic drugs having the potential to be new gold standard technologies in gynecology and urology, according to the award citation: Femivac for the treatment of bacterial vaginosis and trichomoniasis, and Prostavac for the treatment of benign prostatic hyperplasia and acute or chronic prostatitis. Frost & Sullivan, the health care analysts, hosted the Excellence in Healthcare Awards Banquet on February 21 in London, UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze